EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

GLP-1-based therapeutics for cardiorenal protection in metabolic diseases

Ellen M Apperloo, Hiddo J L Heerspink, Daniël H van Raalte, Marcel H A Muskiet

Nephrology Dialysis Transplantation · 30.01.2026 · 41 (2) · 207-219

DOI: 10.1093/ndt/gfaf110 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 25.06.2025. Verfasst von Ellen M Apperloo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Diabetes Mellitus, Type 2, Metabolic Diseases, Hypoglycemic Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the last decade, significant progress has been made in cardiorenal protection for metabolic diseases such as type 2 diabetes (T2D) and obesity. With an expanding range of pharmacological options and continuously evolving guidelines, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered substantial clinical and societal attention for their role in T2D and weight management. GLP-1RAs have consistently demonstrated robust HbA1c- and body weight–reducing efficacy in clinical and real-world studies. In addition, mounting data established their cardiorenal benefits beyond glycaemic control in select high-risk populations. In T2D, GLP-1RAs have been shown to improve both hard cardiovascular and, more recently, relevant kidney outcomes. Meanwhile, in individuals with obesity but without T2D, semaglutide (at a higher dose than in T2D) reduces body weight by up to 15% and lowers the risk of major adverse cardiovascular events by 20%. The success of GLP-1-based therapy fuelled the development of new single molecules that combine GLP-1R agonism with activation of other entero-pancreatic hormone receptors [e.g. glucose-dependent insulinotropic polypeptide (GIP), glucagon and amylin] aiming to achieve complementary and potentially synergistic effects. These next-generation GLP-1-based therapeutics for metabolic diseases, either already available or approaching clinical approval, appear to enhance metabolic and weight-reducing efficacy compared with existing GLP-1RAs. An example is tirzepatide, a dual GLP-1/GIP receptor agonist, which has been approved for both T2D and obesity management, demonstrating up to 22.5% weight loss in phase 3 trials. This review explores the landscape of current and emerging GLP-1-based therapies, their efficacy in managing hyperglycaemia and body weight, recent evidence supporting their cardiorenal benefits and clinical implications of these advancements.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide 1Diabetes Mellitus, Type 2Metabolic DiseasesHypoglycemic AgentsCardiovascular DiseasesObesityHumansGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

GLP-1cardiovascular diseasekidney diseaseobesitytype 2 diabetes

Substanzen

Glucagon-Like Peptide 1Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, location VUMC, Amsterdam, The Netherlands.

Zitieren

APA

Apperloo, E. M., Heerspink, H. J. L., van Raalte, D. H., & Muskiet, M. H. A. (2026). GLP-1-based therapeutics for cardiorenal protection in metabolic diseases. Nephrology Dialysis Transplantation, 41(2), 207-219. https://doi.org/10.1093/ndt/gfaf110

Vancouver

Apperloo EM, Heerspink HJL, van Raalte DH, Muskiet MHA. GLP-1-based therapeutics for cardiorenal protection in metabolic diseases. Nephrology Dialysis Transplantation. 2026;41(2):207-219. doi:10.1093/ndt/gfaf110

BibTeX
@article{Apperloo2026,
  author = {Apperloo, Ellen M and Heerspink, Hiddo J L and van Raalte, Daniël H and Muskiet, Marcel H A},
  title = {GLP-1-based therapeutics for cardiorenal protection in metabolic diseases},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  volume = {41},
  number = {2},
  pages = {207--219},
  doi = {10.1093/ndt/gfaf110}
}
Kostenlos starten →